Özet:

The aim of the work. Diseases of the respiratory system (DRS) remain one of the most common pathology in the structure of morbidity of population ofUkraine. The problem of increasing the efficiency and affordability of treatment of the DRS remains relevant. Thus, in conditions of limited health care resources, and low solvency of the population increasing socio-economic importance of pharmacoeconomic assessment of the availability of pharmaceutical drugs, to what this publication is devoted to. Based on the above, the aim of the study was the analysis of the price indices of the availability of drugs for the treatment of the DRS, including new drugs proposed for implementation in production. Materials and Methods. The analysis of the dynamics of price indices, the liquidity of the prices and availability of mucolytic and expectorant drugs using statistical methods took place. Implemented calculation of the forecast cost of new drugs. Information database: the compendium, price lists, data from the state statistics for 2012–2016. Results and Discussion. In the first stage of research the analysis of price indicators availability of drugs of reference groups of developing combination drug «Bronkhosten» that includes a complex of extracts of herbal raw materials has been realized. The average wholesale prices expectorants and mucolytic drugs for 2013–2016 have been monitored. It has been concluded that overall liquidity indicators Сliq of the drugs of mucolityc and expectorant action for 2012–2016 does not exceed the maximum allowable values, that indicating a stable level of competition in the studied market segment. Indicators of availability of drugs of expectorant and mucolytic actions have been defined. The cost and selling price of the drug on the basis of material calculations of production has been calculated. Conclusions. The analysis of indicators of price indices, liquidity ratios and affordability shows that now the market of drugs for the treatment of respiratory diseases characterized by a wide range of appropriate economic (price) availability of medicines.The calculation of cost of proposed for implementation integrated herbal drug «Bronkhosten» has been made. According to the results of the calculations, the projected wholesale selling prices (including VAT 20 %) will be from 16.00 to 20.00 UAH for packaging. Comparative analysis of prices for the reference drugs allows making a conclusion about the economic feasibility of manufacturing the proposed drug.

Anahtar Kelimeler: